Compare Aurobindo Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ABBOTT INDIA AUROBINDO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 11.0 47.7 23.0% View Chart
P/BV x 2.4 13.7 17.5% View Chart
Dividend Yield % 0.5 0.5 103.9%  

Financials

 AUROBINDO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ABBOTT INDIA
Mar-18
AUROBINDO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8096,110 13.2%   
Low Rs5043,996 12.6%   
Sales per share (Unadj.) Rs281.11,552.2 18.1%  
Earnings per share (Unadj.) Rs41.4188.8 21.9%  
Cash flow per share (Unadj.) Rs50.9196.4 25.9%  
Dividends per share (Unadj.) Rs2.5055.00 4.5%  
Dividend yield (eoy) %0.41.1 35.0%  
Book value per share (Unadj.) Rs199.4796.6 25.0%  
Shares outstanding (eoy) m585.8821.25 2,757.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.3 71.8%   
Avg P/E ratio x15.926.8 59.3%  
P/CF ratio (eoy) x12.925.7 50.2%  
Price / Book Value ratio x3.36.3 51.9%  
Dividend payout %6.029.1 20.8%   
Avg Mkt Cap Rs m384,630107,376 358.2%   
No. of employees `00017.33.3 521.7%   
Total wages/salary Rs m21,3083,937 541.2%   
Avg. sales/employee Rs Th9,500.79,929.3 95.7%   
Avg. wages/employee Rs Th1,229.41,185.1 103.7%   
Avg. net profit/employee Rs Th1,397.91,207.7 115.7%   
INCOME DATA
Net Sales Rs m164,66632,985 499.2%  
Other income Rs m1,0201,170 87.2%   
Total revenues Rs m165,68634,155 485.1%   
Gross profit Rs m37,7185,245 719.1%  
Depreciation Rs m5,580162 3,446.4%   
Interest Rs m77738 2,034.6%   
Profit before tax Rs m32,3806,215 521.0%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1832,203 371.5%   
Profit after tax Rs m24,2294,012 603.9%  
Gross profit margin %22.915.9 144.0%  
Effective tax rate %25.335.4 71.3%   
Net profit margin %14.712.2 121.0%  
BALANCE SHEET DATA
Current assets Rs m121,87822,655 538.0%   
Current liabilities Rs m86,8066,681 1,299.3%   
Net working cap to sales %21.348.4 44.0%  
Current ratio x1.43.4 41.4%  
Inventory Days Days13065 200.5%  
Debtors Days Days6829 234.5%  
Net fixed assets Rs m81,037835 9,699.6%   
Share capital Rs m586213 275.7%   
"Free" reserves Rs m116,21816,715 695.3%   
Net worth Rs m116,80416,928 690.0%   
Long term debt Rs m4,5120-   
Total assets Rs m211,05224,162 873.5%  
Interest coverage x42.7163.7 26.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.81.4 57.2%   
Return on assets %11.816.8 70.7%  
Return on equity %20.723.7 87.5%  
Return on capital %27.436.9 74.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,727369 21,904.6%   
Fx outflow Rs m34,7003,807 911.6%   
Net fx Rs m46,027-3,438 -1,338.8%   
CASH FLOW
From Operations Rs m19,5481,527 1,280.2%  
From Investments Rs m-19,570-2,148 910.9%  
From Financial Activity Rs m8,642-1,024 -843.6%  
Net Cashflow Rs m8,922-1,646 -542.2%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 7.9 100.6%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.1 59.6%  
Shareholders   69,601 18,270 381.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  PLETHICO PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 23, 2019 12:45 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS